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IntroductIon
Muscular dystrophies are characterized by progressive degenera-
tion and weakness of multiple muscle groups depending on the 
specific dystrophy. Duchenne muscular dystrophy (DMD) is an 
X-linked pathology due to the absence of dystrophin in muscle 
fibers.1,2 The first symptoms of the disease appear during early 
childhood, usually before 3 years of age, and death occurs in the 
mid to late twenties.
The dystrophin gene, called DMD gene, extends over 2.4 
megabases of the X chromosome, thus ~90 times the size of most 
genes. It contains 79 exons that code for a 14 kb mRNA.3,4 Its 
translation generates a large protein of 3,685 amino acids with a 
molecular size of 427 kDa5 called dystrophin. This protein is local-
ized beneath the sarcolemma of the muscle fibers.6
Dystrophin can be divided into four main regions (Figure 1a). 
The N-terminal domain interacts with actin filaments.7 The cen-
tral rod domain also links to actin filaments8 and, in addition, to 
neuronal nitric oxide synthase (nNOS).9 This enzyme is impli-
cated in several physiological functions of the muscle such as its 
regeneration and its contraction.10 The central domain also con-
tains four hinge regions that provide flexibility.11 The third region 
is the cystein-rich domain that interacts with the sarcolemmal 
β-dystroglycan, which in turn interacts with the transmembrane 
α-dystroglycan.12 The dystrophin C-terminal region is associated 
with α-, β-, and γ-syntrophins.13–15 Since dystroglycans and syn-
trophins are also linked to other proteins, dystrophin thus inter-
acts with many proteins in a complex called dystrophin-associated 
glycoprotein complex (DGC) (Figure 1b).16–19 The main function 
of dystrophin is to stabilize and link the muscle fiber cytoskeleton 
to the membrane. The lack of functional dystrophin results in the 
loss of the DGC, thereby rendering the muscle fibers less resistant 
to mechanical stress.16,20
In DMD, the DMD gene mutations almost always result in a 
premature stop codon due to frameshift mutations or nonsense 
mutations. There are >4,700 different mutations divided into 
three main categories: deletion of one or more exons, duplica-
tion of one or more exons and small mutations. Depending on 
the cohorts studied, the proportion of these categories varies 
from 60 to 80% for deletions, from 7 to 11% for duplications and 
from 10 to 30% for more subtle DNA changes including nonsense 
mutations, splice-site mutations, and small insertions/deletions 
that disrupt the reading frame.21–26 As mentioned, most of the 
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duchenne muscular dystrophy (dMd) is a genetic disease affecting about one in every 3,500 boys. this X-linked 
pathology is due to the absence of dystrophin in muscle fibers. this lack of dystrophin leads to the progressive 
muscle degeneration that is often responsible for the death of the dMd patients during the third decade of 
their life. there are currently no curative treatments for this disease but different therapeutic approaches are 
being studied. Gene therapy consists of introducing a transgene coding for full-length or a truncated version 
of dystrophin complementary dnA (cdnA) in muscles, whereas pharmaceutical therapy includes the use of 
chemical/biochemical substances to restore dystrophin expression or alleviate the dMd phenotype. over the 
past years, many potential drugs were explored. this led to several clinical trials for gentamicin and ataluren 
(Ptc124) allowing stop codon read-through. An alternative approach is to induce the expression of an inter-
nally deleted, partially functional dystrophin protein through exon skipping. the vectors and the methods 
used in gene therapy have been continually improving in order to obtain greater encapsidation capacity and 
better transduction efficiency. the most promising experimental approaches using pharmaceutical and gene 
therapies are reviewed in this article.
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deletions in the DMD gene result in a frameshift.27 Those that do 
not produce a frameshift result in the production of an internally 
deleted dystrophin and give rise to a dystrophy called Becker mus-
cular dystrophy (BMD).28 The BMD phenotype varies according 
to the functional loss of the missing exons but is generally less 
severe than DMD.29–31 For example, a deletion in the rod domain 
will often be less severe than a deletion in N-terminal. The life 
expectancy of BMD patients is also variable: some may suffer life 
threatening complications in their late twenties and have a simi-
lar life expectancy as DMD patients whereas many live a normal 
lifespan beyond 50 years of age.
DMD symptoms are very severe. Thus, even if there are 
currently no curative treatments for this disease, the medical 
monitoring and the care coverage of these patients contribute to 






























Figure 1 the dystrophin protein. (a) Schema representing the four main domains of dystrophin: the N-terminal part, central rod domain (contain-
ing 24 spectrin-like repeats and four hinge domains), cystein-rich region and the C-terminal part. The protein binding domains are also indicated. 
(b) Diagram of the dystrophin-associated glycoprotein complex (DGC). This complex includes dystrophin with its C-terminal (Ct), cysteine-rich (CR), 
and N-terminal (Nt) regions as well as proteins associated in this complex. DG, dystroglycan; nNOS, neuronal nitric oxide synthase; Sg, sarcoglycan; 
Syn, syntrophin. Modified from Odom et al.19
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prevention of some complications and to improvement in their 
quality of life. For that purpose, the follow-up of patients must 
be considered at various levels: rehabilitation, cardiac, pulmonary, 
orthopedic, psychosocial, and nutrition.32,33
Following the initial open-label trials of corticosteroids, the 
potential benefit of prednisone was clearly demonstrated >20 years 
ago in a double-blind randomized controlled trial for 6 months in 
a study of >100 boys.34 Subsequent reports showed equal benefit 
using deflazacort, a sodium-sparing steroid.35 These results were 
confirmed by other studies (see refs. 32,36,37 for an exhaustive list 
of these studies). Long-term follow-up of open-label administra-
tion of corticosteroids reveals prolonged ambulation for about 2 
years. In addition, the lower prevalence of scoliosis through the 
use of long-term corticosteroid treatment represents a significant 
change in the natural progression of DMD.38 Prednisone prescrip-
tion to DMD patients is now openly authorized in many countries 
but many patients are forced to stop taking the drug because of 
unwanted side effects that include weight gain, bone demineral-
ization, vertebral compression fractures, hypertension, and/or 
behavior disorders.
Besides the DMD patient’s follow-up, different therapeutic 
approaches are currently in development to improve the DMD 
phenotype. This review focuses more specially on the current sta-
tus of pharmaceutical and of gene therapy approaches in DMD. 
We have not reviewed the different potential cell therapies for 
DMD; however, some ex vivo gene therapies have been included.
PhArMAceutIcAl APProAch
The great advantage of a pharmacological approach is that nearly 
all drugs can be delivered systemically (orally, intravenously, sub-
cutaneously) and thus will reach and potentially treat all muscles 
which is critical for clinical success in DMD. However, the devel-
opment and testing of new drugs for the DMD population is far 
from being a simple task.
dystrophin restoration approaches
Stop codon read-through. About 10–15% of DMD patients have a 
mutation that converts an amino acid into a premature nonsense 
codon, while the rest of the mRNA is unaffected.21–26 Some drugs 
have been shown to enable stop codon read-through by introduc-
ing an amino acid at the premature stop codon to continue the 
mRNA translation. This phenomenon called “stop codon read-
through” has been intensively investigated.
Gentamicin: Gentamicin is an aminoglycoside antibiotic inter-
acting with the translational machinery (40S ribosomal subunit) 
when it recognizes a stop codon.39–41 This interaction induces the 
introduction of an amino acid at stop codons in the mRNA and 
thus allows the translational machinery to continue the mRNA 
translation.42,43 It specially occurs in premature stop codons since 
the context of nucleotide sequences surrounding nonsense muta-
tions and regular stop codons are different.44 Gentamicin was 
tested as a therapeutic approach for DMD. When used in dystro-
phic (mdx) mice, this drug induced up to 20% dystrophin-positive 
fibers.45 After this positive result, two clinical trials on DMD and 
BMD patients were undertaken. However, the results were moder-
ate46,47 as was also the case for some further studies in animals.48,49 
Recently, a clinical trial showed that a 6 months gentamicin 
administration resulted in up to 15% dystrophin expression in 
three DMD patients, lower percentages in three other patients, 
and no expression in the remaining patients.50 The different results 
obtained in mouse and in human are probably due to the presence 
of different gentamicin isomers, which are not all equally potent in 
inducing read-through41 and since each gentamicin batch consists 
of a mix of different isomers, some batches may be more effective 
than others.
Given that gentamicin has variable effects and exhibits some 
toxicity, less toxic effective derivatives of this drug need to be 
developed for an effective DMD treatment.
Ataluren: Ataluren (PTC124) is a new molecule recently iden-
tified by PTC Therapeutics (South Plain Field, NJ). It is presumed 
to work similarly to gentamicin except that PTC124 binds to the 
60S ribosomal subunit.51 Its efficiency is comparable to gentami-
cin in mouse: between 20 and 25% dystrophin-positive fibers were 
observed in treated mdx mice.52 Three phase II clinical studies 
began on DMD and BMD patients but these studies were halted 
prematurely on March 2010 since the predetermined primary out-
come (30 m improvement compared to placebo in the 6-minute 
walk test) was not reached53 while ataluren was generally well tol-
erated in DMD patients.54 No information is available concerning 
the dystrophin expression in treated muscles.
Even though gentamicin and ataluren have shown good effi-
ciency in the mdx mouse model, the clinical studies that have been 
done up to date showed that these drugs still need further improve-
ments before they can be used clinically in DMD patients.
Exon skipping. In BMD patients, dystrophin is internally deleted, 
but still partially functional due to the presence of the essential N- 
and C-terminal domains. Using antisense molecules which were 
able to interfere with splicing signals, the skipping of the targeted 
specific exons in the dystrophin pre-mRNA can restore the open 
reading frame and allow the expression of an internally deleted 
but functional dystrophin in DMD patients (Figure 2). These 
molecules are small synthetic modified RNAs or DNAs called 
antisense oligonucleotides (AOs) able to bind specific intronic 
or exonic sites of pre-mRNA. Annealing to selected splice mo-
tifs, the AO essentially masks the targeted exon from the splicing 
machinery, thereby promoting specific exon exclusion from the 
mature mRNA. Two types of AO are mainly used: 2′-O-methyl-
phosphorothioate (2OMP) and phosphorodiamidate morpholino 
oligomer (PMO) (Supplementary Figure S1).
2′-O-methyl-phosphorothioates: 2OMPs contain around 20 
nucleotides and are obtained by modifying the classic synthesis 
of oligonucleotides.55 The first modification is the replacement of 
the negatively charged oxygen by sulfur. The second one is the 
methylation of the hydroxyl group at the 2nd position of ribose. 
These modifications make the AOs more resistant to nucleases, 
improve their affinity for RNA, provide favorable pharmacokinetic 
properties and prevent RNase H to induce cleavage of RNA:RNA 
hybrids.56–58
Several 2OMPs designed to target several human DMD exons 
were tested with success in DMD patient-derived myotubes.59,60 In 
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parallel, 2OMPs were designed to target the exon 23 of the mouse 
DMD gene since the nonsense mutation of mdx mouse is localized 
in this exon. Intramuscular administration of an AO targeting the 
exon 23 donor splice-site in these mice induced the restoration of 
dystrophin (without the exon 23) in the treated muscles.61 These 
AOs were also intravascularly injected in mdx mice. Treated mice 
showed dystrophin restoration in many muscles.62 However, low 
levels of dystrophin restoration were detectable in the heart.63 A 
study demonstrated that repeated 2OMP injections increased the 
AO efficiency without increasing its toxicity.62 A subcutaneous 
2OMP injection has also been tested and this type of injection 
showed better pharmacokinetics and pharmacodynamics than 
intramuscular or intravenous injections.64
After these positive results in the mdx mouse model, a clini-
cal trial on four DMD patients with the PRO051/GSK2402968 
(2OMP targeting exon 51) was done. The muscle injected with 
0.8 mg of this 2OMP showed 64–97% dystrophin-positive fibers 
(not corrected for positive muscle fibers in saline-injected contral-
ateral muscle) with a level of dystrophin expression between 17 
and 35%.65 No adverse effects were found in the treated muscles. 
A phase I/II clinical trial, in which this same AO was injected sub-
cutaneously, was recently completed and showed that this AO was 
well tolerated in all patients and that novel dystrophin expression 
was detected in each treated patient in a dose dependent manner.66 
A phase III study has started with this AO on DMD patients.67
Despite the fact that long-term toxicity studies in animal mod-
els with 2OMP are lacking, this approach seems promising.
Phosphorodiamidate morpholino oligomer: Similar to 2OMPs, 
PMOs (commonly referred to as morpholinos) are obtained by 
modifying the classic synthesis of oligonucleotides. Their ribose 
is replaced by a morpholine ring and the oxygen present in the 
phosphodiester link (the one that is not negatively charged) is 
replaced by a nitrogen atom. These modifications allow morpholi-
nos to be biologically stable68 and have antisense properties.69
Exon 23 of the mouse DMD gene was the first target of mor-
pholinos. Restoration of dystrophin was observed in the treated 
mdx mouse muscles when morpholinos were intramuscularly 
injected70 and in many muscles when intravenously71 or intrap-
eritoneally injected.72 A partial restoration of dystrophin in the 
heart of mdx mice was also shown but the morpholino dose used 
was 50 times superior to the one used to treat skeletal muscles.72 
Recent studies of long-term repeated systemic treatment of mdx 
mice over a year with naked PMO at doses of 5 and 50 mg/kg 
have shown significant improvement in pathology and complete 
normalization of locomotor behavior without signs of renal or 
hepatic toxicity.73 A morpholino designed to restore dystrophin 
expression in dystrophic (golden retriever muscular dystrophy) 
dogs was also synthesized and intravenously injected in these 
dogs. Five months later, treated dogs showed about 25% dystro-
phin-positive fibers throughout the body with a global improve-
ment in muscle pathology in PMO-treated dogs compared to 
pretreated and untreated control dogs.74 No significant signs of 
toxicity were found.
To enhance the cellular uptake of PMOs, they can be conju-
gated to peptides or other conjugates. The delivery of a morpholino 
conjugated with a dendrimeric octaguanidine (Vivo-Morpholino) 
was efficient to induce dystrophin expression in mdx mouse mus-
cles.75 Indeed, repeated injections at biweekly intervals achieved 
near 100% dystrophin-positive fibers in many skeletal muscles 
without eliciting a detectable immune response; the dystrophin 
restoration in the cardiac muscle reached up to 40%. PMOs con-
jugated with arginine-rich cell-penetrating peptides,76 called 
pPMOs, also produced excellent restoration of dystrophin expres-
sion in mdx mice.77,78 A pPMO targeting exon 23 was applied as 
well in utrophin−/− mdx mice by intraperitoneal injection. Whereas 
untreated animals typically died by 15 weeks of age, treated ani-
mals showed few signs of weakness, improved histopathology and 
appeared essentially normal at 1 year of age.79 A muscle-targeting 
heptapeptide (MSP) fused to an arginine-rich cell-penetrating 
peptide (B-peptide) and conjugated to a PMO, called B-MSP-
PMO, was also shown to be efficient for restoring dystrophin in 
mdx muscles.80 Indeed, using an intravenous dose of 6 mg/kg of 
B-MSP-PMO administered biweekly over the course of 12 weeks, 
the dystrophin expression was found at a level of 100% in several 
muscles except for the heart. These pPMO seem well tolerated in 
mdx mice. Indeed, a pPMO targeting the exon 23 of the mouse 
DMD gene exhibited no toxic effects in kidneys at either 20 mg/
kg weekly injection to the wild-type mice for 6 weeks or 30 mg/kg 
biweekly injection to mdx mice for 3 months. However, the same 
peptide conjugated to the PMO targeted to human exon 50 (AVI-
5038) was found to cause mild tubular degeneration in the kidneys 
of nonhuman primates at 9 mg/kg weekly injections for 4 weeks.81
To target more dystrophin mutations occurring in DMD 
patients, other exons such as the exon 51 in mdx52 mice were tar-
geted.82 In addition, it is possible to remove in-frame exons from 
the dystrophin pre-mRNA and induce specific internally deleted 
dystrophin by using AOs. This has been done for exons 19/20 and 
52/53 in wild-type mice.83
Deletion of exon 50
Exon 49
Exon 49
Intron 49/50 Exon 51
Exon 51
Exon 49 Exon 52
Exon 52Intron 51












Figure 2 example of exon skipping in duchenne muscular dystrophy 
(dMd) patient who has a deletion of exon 50. (a) The absence of 
exon 50 in the dystrophin gene leads to an out-of-frame mRNA creating 
a premature stop codon in exon 51, thus aborting dystrophin synthesis 
during translation. (b) Using an antisense oligonucleotides (AO) target-
ing exon 51, this exon is skipped during splicing. This restores the open 
reading frame of the transcript and allows the synthesis of an internally 
deleted dystrophin. Modified from Van Deutekom et al.65
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After these positive results in animal models, a clinical trial 
in seven DMD patients was undertaken to skip exon 51 and thus 
to restore the reading frame of their dystrophin mRNA using 
unmodified morpholinos. The morpholino (AVI-4658) was intra-
muscularly injected and biopsies were taken 3–4 weeks later. Two 
patients were treated with a low dose of this morpholino (0.09 mg) 
and five patients with a higher dose (0.9 mg). Only the patients 
receiving the higher dose produced dystrophin although exon 
skipping was observed in all patients by reverse transcriptase PCR. 
In the five patients receiving the higher dose, the muscles injected 
with the AO showed 44–79% dystrophin-positive fibers (corrected 
for positive fibers in saline-injected contralateral muscle) with a 
level of dystrophin expression between 22 and 32%.84 No signs of 
toxicity were observed. After these encouraging results, a systemi-
cally delivered morpholino phase Ib/II clinical trial was under-
taken. According to a press release from AVI Biopharma (Bothell, 
WA),85 19 DMD patients were enrolled in six dose cohorts (0.5, 
1, 2, 4, 10, or 20 mg/kg) and treated during 12 weeks by weekly 
intravenous infusion. Some patients expressed dystrophin-posi-
tive fibers; those treated with the higher doses of morpholino had 
more uniform and widespread dystrophin-positive fiber distribu-
tion than patients who received lower doses. The morpholino was 
well tolerated in all patients. A phase II clinical trial is currently in 
preparation to evaluate higher weekly doses of AVI-4658 (50 and 
100 mg/kg).85
Although pPMO seems to cause some toxicity in nonhuman 
primates, there are other ways to modify the peptide conjugate, 
which are hopefully less toxic, to allow clinical development for 
DMD patients.
Modification of the DMD gene with meganucleases or zinc 
finger nucleases. A new alternative treatment for DMD relies 
on the restoration of the dystrophin reading frame by inducing 
a micro-deletion or a micro-insertion in the DMD gene.86 This 
can be done by inducing double strand breaks at the end of the 
exon, which precedes a deletion, or at the beginning of an exon, 
which follows a deletion. These double strand breaks can be in-
duced with specially engineered meganucleases or zinc finger 
nucleases. They are spontaneously repaired by a process called 
nonhomologous end-joining, which introduces a micro-insertion 
or a micro-deletion. Alternatively, double strand breaks can be 
repaired by homologous recombination by providing a donor 
plasmid containing the coding sequence that is deleted in the pa-
tient’s genome.
other approaches
Myostatin. A potential therapeutic method to improve muscle 
strength is to block myostatin. Myostatin is a member of the 
transforming growth factor-β family implicated in muscle size 
regulation. Indeed, in the myostatin gene knockout mouse, 
robust muscular hypertrophy and hyperplasia are observed.87 
Antibodies against myostatin were produced and intraperito-
neally injected in mdx mice. The treated mice showed muscular 
hypertrophy, muscle strength increase, and histological im-
provement.88 There are also other methods to block the myosta-
tin pathway such as the use of follistatin89 or of myostatin pro-
peptide.90 Another approach is to directly mutate the myostatin 
receptor, the activin type-II receptor91 or to inject a soluble form 
of this receptor.92 All these approaches led to improvements of 
the treated mouse phenotype similar to that observed in myo-
statin−/− mice. Recently, the use of destructive exon skipping 
of the myostatin pre-mRNA induced by 2OMP and PMO has 
been described to induce skeletal muscle hypertrophy, which 
along with dystrophin exon skipping (see above) may thus pro-
vide a potential combined antisense strategy to simultaneously 
reactivate dystrophin expression and increase muscle bulk.93 In 
a recent clinical trial, the use of an antibody against myostatin 
(MYO-029) was undertaken. Although the antibody was well 
tolerated, no muscle strength improvements were detected per-
haps due to a lower dose of antibody.94 Other clinical trials with 
myostatin inhibitors are currently undertaken by at least four 
biotechnology and pharmaceutical companies.95
Utrophin. Utrophin shares 80% sequence identity with dystro-
phin and is expressed in the muscles during embryonic devel-
opment.96 However, in adult myofibers, it is located only at the 
neuromuscular junction and at the myotendinous junctions. 
Utrophin is over-expressed in muscle fibers of dystrophic mice 
and of DMD patients.97,98 Since it has sequence homology with 
dystrophin, it was suggested that its upregulation could slow 
down DMD development. When its expression is increased three- 
to fourfold in transgenic mdx mice, their phenotype is similar to 
wild-type mice.99 Therefore, an increase of the utrophin expres-
sion may be a potential therapy to improve DMD patients. The 
injection of heregulin in mdx mice increased utrophin expression 
by two to threefold and led to histological improvements.100 The 
injection of l-arginine or nitric oxide also allowed utrophin up-
regulation in mdx mice.101 Recently, the intraperitoneal injection 
of a TAT-utrophin protein in mdx mice increased their muscle 
strength.102 A drug developed by Summit PLC (C110/BM195) to 
upregulate the utrophin expression was carried out by BioMarin 
pharmaceuticals in a phase I clinical trial with normal individu-
als. No adverse effects were reported but the pharmokinetics of 
the drug did not allow them to continue the development of this 
drug. Summit PLC is currently working on a new formulation, 
which may improve the pharmokinetics. Further investigation in 
increasing utrophin expression is required since the molecules 
tested so far in mdx mice did not increase utrophin expression 
sufficiently to completely suppress the symptoms due to the dys-
trophin deficiency in mdx mice.103,104 Moreover, utrophin does 
not seem to anchor nitric oxide synthase at the sarcolemma like 
dystrophin does, thus leading to a premature muscle ischemia.105 
However, the levels of utrophin upregulation may be sufficient to 
alleviate most of the DMD symptoms.
Gene therAPy
Since the first clinical trial of gene therapy in 1990,106 there has 
been a strong interest for this therapeutic approach. However 
in 1999, a major setback occurred due to the death of a patient 
treated with an adenovirus for ornithine transcarbamylase defi-
ciency.107 This death is believed to have been triggered by a severe 
innate immune response to the adenoviral vector. In 2002, another 
death occurred in a clinical trial for severe combined immuno-
deficiency with the use of a retrovirus where one of the treated 
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patients died due to the activation of an oncogene.108 However, 
the fatality rate of gene therapy is still much lower than that of the 
standard bone marrow transplantation treatment for severe com-
bined immunodeficiency patients.109 Moreover, >45 patients have 
now been treated via gene therapy, resulting in one death and >40 
cures. Gene therapy is thus an appealing approach to cure many 
hereditary diseases such as DMD.
Gene therapy in DMD consists of the introduction of a func-
tional copy of the DMD gene in muscle fibers with the aim of restor-
ing muscle function including force generation and resistance to 
muscle contraction induced damage. The concept of dystrophin 
internally deleted genes that would fit the packaging capacity of 
small viral vectors came from clinical observations that some 
BMD patients with internally deleted dystrophins could main-
tain ambulation for many decades. This gave rise to the concept 
of mini-dystrophin (mDYS) or micro-dystrophin (µDys). Gene 
therapy is divided in two distinct categories: those using viral vec-
tors to transfer the gene are referred to as “viral gene therapy” and 
those employing naked DNA as “nonviral gene therapy”.
Internally deleted dystrophin genes
In gene therapy, the transgenes generally contain complementary 
DNA (cDNA) corresponding only to coding regions of a gene, i.e., 
exons without introns. The dystrophin cDNA size is about 11 kb 
and is called full-length dystrophin (FLDYS). Apart from this 
FLDYS, several mDYS and µDys internally deleted versions exist 
(Figure 3). Indeed, a BMD patient with a deletion of the exons 
17–48 in the DMD gene was reported to have only a mild dystro-
phic phenotype.30 The missing region was located in the spectrin-
like repeats of the rod domain resulting in an internally deleted 
dystrophin with only eight of these repeats instead of 24. The 
corresponding transgene was thus constructed110 and other, even 
smaller, truncated versions were designed subsequently.111,112 These 
constructions were called mDYS, or µDys when the C-terminal 
part is also missing.
Several transgenic mice expressing these internally deleted 
dystrophins were generated and analyzed112–115; all these mice 
showed the restoration of the DGC. The simple fact of restoring 
the DGC improves the muscle histology as well as the reduced 
leukocyte infiltration and the decreased number of centro-nucle-
ated muscle fibers. The muscle strength is also increased but does 
not reach wild-type levels. However, the observed improvements 
vary depending on which exons are deleted. The use of internally 
deleted dystrophins is attractive but the best phenotypic restora-
tions are still obtained with the use of FLDYS.
Viral gene therapy
Different viral vectors could be used for DMD gene therapy. 
Adenoviral vectors show poor efficiency in adult animal models 
compared to newborns. Moreover, the use of adenoviral vectors is 
complicated since half of the human population already has neu-
tralizing antibodies against the adenoviral capsid and also tends 
to be far more immunogenic than adeno-associated viral vectors 
(AAV) and retroviral vectors. Due to these limitations, only AAV 
and lentiviral vectors are described below.
AAV. There are many different AAV, i.e., >100 different sequences 
are available. Some of the differences lead to different serotypes. 
The serotypes 1, 2, 6, 8, and 9 are more frequently used for muscle 
gene therapy. The AAV vector is the only efficient vector for local 
or systemic delivery to the skeletal muscle and heart116,117 but its 
packaging capacity limits the size of the dystrophin transgene.
AAV1118 and AAV2111 carrying transgenes encoding for µDYS 
were injected in mdx mouse muscles with success. Indeed, up to 
80% dystrophin-positive fibers were found in the treated muscles. 
These AAV injections also restored the DGC. The results on the 
mdx mouse model being conclusive, experiments using AAV vec-
tors were done in larger animal models. AAV6 and AAV8 coding for 
µDYS were injected in the dog model. Although dystrophin expres-
sion was observed, cytotoxic immune response against the viral 
capsid was detected,119,120 which has also been observed for other 
transgenes delivered by AAV vectors in the dog model.121 The AAV 
vector was also tested in nonhuman primates. Five months after the 
intramuscular injection of an AAV8 coding for µDYS, the transgene 
expression reached 80% in the treated muscle but this percentage 
decreased to 40% when the animal already had pre-existing anti-
bodies against the AAV.122 In small rodent studies, AAV vectors 
rarely cause cellular immune responses against either the capsid 
proteins or the transgene products. But in large animal and human 
studies, variable immunological outcomes have been observed.
Recently, a clinical trial was undertaken on six DMD patients 
with an AAV vector coding for a functional µDYS. Of the six treated 
patients, two showed pre-existing T-cells recognizing the rare dys-
trophin-positive revertant fibers that presented peptide epitopes 
deemed by the host as nonself. This was detected in ELISpots of 
peripheral blood mononuclear cells before and after intramuscular 
injection of the AAV.123 Another patient had T-cells recognizing 
an epitope that encoded the transgene product but absent in the 
revertant fibers. Although the clinical trial was safe and muscle 
biopsies from the gene vector-treated arms and the contralateral 
control arms showed no difference in lymphocytes infiltration, 
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Figure 3 dystrophin versions. The full-length dystrophin cDNA (11 kb) is represented at the top. The middle schema represents an example of a 
mini-dystrophin cDNA with an H2-R18 deletion; the approximate size of mini-dystrophins is about 6 kb. The bottom representation is a schema of a 
micro-dystrophin cDNA (around 4 kb) with an R3-R21 and C-terminal deletion.
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these intriguing findings strongly suggest that additional work is 
required to determine how many patients have T-cells to dystro-
phin epitopes and whether those T-cells will prevent successful 
gene therapy in DMD. In addition, choices of AAV vector serotypes 
and promoters may also make an impact on the clinical outcome.
Exon skipping was also investigated in combination with AAV 
vectors. AAV1 coding for the U7 snRNA or U1 small nuclear RNA 
(snRNA) genes modified to target the mouse dystrophin exon 23 
were injected in mdx mice. The expression of the internally deleted 
dystrophin was observed up to 3 months following the injection of 
an AAV1 coding for the U7 snRNA124 and for at least 1 year and 
half with an AAV1 coding for the U1 snRNA.125 These results are 
encouraging but this approach has to be further investigated in 
larger animals such as nonhuman primates or dogs.
AAV vectors were also used to interfere with the myostatin 
pathway. An AAV vector coding for the myostatin propeptide, a 
myostatin inhibitor, was designed and injected in mdx mice. Muscle 
hypertrophy leading to phenotypic improvements was observed in 
the treated mice.126 Dogs were also treated with the same vector. 
Unfortunately, few parameters were studied in this experiment and 
only the hypertrophy of some muscles was noted.127 In contrast to 
the other dog studies using AAVs coding for µDYS, no immune 
responses against the AAV capsid were observed in this study. In 
the mouse, a recent experiment used an AAV coding for the activin 
type-II receptor to block the myostatin pathway. The effects of this 
AAV injection were similar to those observed in the mouse follow-
ing the injection of the purified activin type-II receptor alone.128
The results obtained with AAV vectors are interesting for the 
development of a DMD therapy. Nevertheless long-term studies 
of the transgene expression and the immune response against the 
capsid will be required before this can be considered as potential 
treatment for DMD.
Lentivirus. The lentivirus encapsidation size is limited to carry 
the mDYS. Thus, a lentiviral vector carrying this internally delet-
ed DMD gene was intramuscularly injected in adult and newborn 
mdx mouse muscles. The best results were obtained in younger 
mice where 65% of muscle fibers expressed the transgene.129 In ad-
dition, better strength and protection against contraction induced 
injury were observed in the treated muscles. The lentivirus injec-
tion also transduced satellite cells.130 Despite favorable results in 
small animals, no studies are available for larger animal models. 
Moreover, the random integration of lentiviral vectors, accord-
ing to the target tissues and the enhancers used in a construct, 
predisposes to induction of tumors (insertional mutagenesis) 
even though they have not been observed to date in the described 
experiments.
Lentivirus can also be used to genetically modify cells, which 
can be transplanted or injected in animal models or eventually 
in patients. This technique is called ex vivo gene therapy. A len-
tiviral vector coding for µDYS was used to integrate this gene in 
the genome of side population cells, which were then intrave-
nously injected in mdx mice. Only 1% of muscle fibers expressed 
the transgene in the treated muscles,131 though this percent-
age was increased to 5% when these cells were intra-arterially 
injected.132 Dystrophic dog mesoangioblasts were also transduced 
with a lentiviral vector coding for the human µDYS and intra-
arterially injected in the same dogs.133 The treated dogs showed 
good expression of human µDYS but two of the three treated dogs 
died of pneumonia during the experiment. The cause of this death 
was not explained by the investigators but the accumulation of 
the injected cells in the lungs could be involved in this mortal-
ity. Other cell types such as human and nonhuman primate myo-
blasts were transduced with human µDYS and transplanted with 
success in immunodeficient mouse and in nonhuman primate 
muscles respectively.134 A lentiviral vector coding for dog µDYS 
was also used to transduce human and dystrophic dog myoblasts. 
Subsequently, these cells were transplanted in mouse muscles and 
transgene-positive fibers were observed in the treated muscles.135
In addition to the possibility of delivering an internally deleted 
dystrophin, the lentiviral vector may be used to induce exon skip-
ping as well. A lentiviral vector coding for the U7 snRNA gene 
modified to induce the skipping of human dystrophin exon 51 was 
designed. Myoblasts of DMD patients having a deletion of exons 
49 and 50 were transduced with this lentivirus and transplanted in 
immunodeficient mouse muscles. One month later, the expression 
of internally deleted dystrophin (without the exons 49–51) was 
detected in the treated muscles.134 This approach was also used 
successfully with AC133+ cells.136
The use of lentiviral vector is promising for DMD but its effi-
cacy and the risk of tumorigenicity from cells transduced by direct 
injection of a lentiviral vector or by ex vivo genetic modification 
need to be evaluated in clinical trials.
nonviral gene therapy
Nonviral gene therapy allows the introduction of a transgene into 
a tissue without using a viral vector. Thus, the main advantage of 
this method is to avoid any immune response due to viral capsids 
or other viral proteins. There are also no limitations concerning 
the transgene size but the transfection efficiency of nonviral gene 
therapy is progressively reduced with the increasing plasmid size.
Naked DNA. The simplest method to deliver a plasmid into mus-
cle is its direct injection. Plasmids coding for µDYS and for FLDYS 
were injected in mdx mice110; however, the transfection efficiency 
was very low. Nevertheless, there is a possibility for prolonged 
transgene expression in muscles since muscle fibers are postmitot-
ic. A phase I clinical trial was undertaken in 2004 on nine dystro-
phic patients137 that were intramuscularly injected with a plasmid 
coding for human FLDYS. The three treated DMD patients just 
showed rare dystrophin-positive fibers. In the six treated BMD pa-
tients, the average level of dystrophin expression was slightly higher 
(about 3%). Although the application of naked DNA is appealing 
since this method is fast and the plasmids are easy to produce, the 
efficiency of direct intramuscular injection is currently too low to be 
clinically relevant. To improve gene delivery, chemical and physi-
cal methods can be used. However, due to the low effectiveness of 
chemical methods in vivo, only physical approaches are included in 
the present review.
Physical approach 
Hydrodynamic pressure: Good expression levels were obtained fol-
lowing a rapid injection of a large quantity of plasmid DNA coding 
for luciferase or β-galactosidase.138 This intravenous injection of a 
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large volume while using a tourniquet to occlude blood flow allows 
good dissemination of the naked DNA in muscles.139 Indeed, the 
intravascular pressure induced the formation of transient pores in 
the endothelium of blood vessels allowing macromolecules, such 
as plasmids, to leak into the surrounding muscle and thereby access 
the muscle fibers.140 The safety of this method was demonstrated 
in mice and in nonhuman primates.139,141 The hydrodynamic limb 
vein injection used in mdx mice with a plasmid coding for FLDYS 
resulted in dystrophin expression in up to 20% of muscle fibers for 
>1 year.142 The phenotype of the treated mice was also improved. 
Golden retriever muscular dystrophy dogs were also treated with 
this technique. The procedure appeared safe in the treated animals 
and enabled to obtain dystrophin expression but further work is 
required to determine the exact level of dystrophin expression.143 
This approach seems thus promising to introduce naked DNA in 
muscles.
Electroporation: A second method to improve the efficiency of 
muscle transfection is electroporation. The electric field used in 
this method enhanced the uptake of a plasmid previously injected 
in the muscle.144,145 Indeed, the electric pulses permeabilized the 
cellular membrane, creating transient pores that facilitated the 
plasmid entry into the cell. However, these pores also increased 
calcium entry and activated proteases.146 Therefore, it is impor-
tant to select voltage settings, which allow maximal efficiency 
with the least amount of damage. As with the hydrodynamic 
pressure method, the electroporation of naked DNA in muscles 
resulted in transgene expression for >1 year.147 The heart can also 
be treated by electroporation according to a recent research arti-
cle.148 A study showed that satellite cells can be transfected with 
this technique.149 However, this study has not been confirmed. 
According to Schwann’s equation, the threshold intensity of the 
applied electric field necessary to obtain membrane permeabi-
lization is inversely proportional to the cell radius.150 Since the 
radius of satellite cells is smaller than that of muscle fibers, the 
satellite cells and the muscle fibers cannot be electroporated 
simultaneously.
Since its first use in a clinical trial in 1991,151 plasmid elec-
troporation has proven to be safe and effective for transgene deliv-
ery to several tissues.152–154 In the DMD context, a plasmid coding 
for mouse FLDYS was electroporated in mdx mouse muscles. The 
electroporated muscle fibers expressed the transgene for at least 1 
month and exhibited a reduced number of centro-nucleated mus-
cle fibers as well.155,156 Dog FLDYS was also introduced with suc-
cess in dystrophic dog muscle.157 In this case, a specific immune 
response was observed in the treated dog muscle. Further studies 
are thus required to determine whether this immune response was 
against dystrophin or against the product of another transgene 
also present in the plasmid.
dIscussIon
DMD is a devastating pathology leading to severe muscle weak-
ness. This disease is due to the lack of dystrophin in smooth, 
cardiac, and skeletal muscles. Although there are currently no 
curative treatments for DMD, several therapeutic approaches are 
undergoing clinical evaluation such as pharmaceutical approaches 
and gene therapy.
Pharmaceutical approaches
The stop codon read-through is one of pharmaceutical approaches. 
The last clinical trial with ataluren showed that it was unable 
to achieve its primary outcome for improved muscle function. 
The long-term gentamicin clinical trials gave mixed results and 
showed too many toxicity issues to consider this antibiotic as a 
feasible approach to treat DMD patients having nonsense muta-
tion. Moreover, stop codon read-through would only be relevant 
to only about 10 to 15% of DMD patients.
Exon-skipping can in theory be applied to 80% of DMD 
patients.25 This method has shown its efficiency in mouse and dog 
models. Clinical trials using 2OMPs and morpholinos were also 
undertaken on DMD patients. In both cases, dystrophin expres-
sion was observed in the treated muscles and no significant adverse 
effects have been encountered. Only the results of intramuscu-
lar exon skipping trials have been published so far with results 
restricted to the site of delivery. However, the first results on the 
clinical trials using a morpholino (AVI-4658) or a 2OMP (PRO051/
GSK2402968) systemically delivered showed good dystrophin 
expression.66,85 Even though there are no long-term toxicity studies 
(>6 months) available on 2OMPs and morpholinos in nonhuman 
primate, these two compounds are promising for DMD.
Currently, no molecules upregulate utrophin expression suf-
ficiently to restore the phenotype of dystrophic mouse models. 
Therefore, utrophin upregulation must be further improved before 
applying it in DMD.
Gene therapy
Another method to obtain a functional dystrophin is to introduce 
a cDNA in muscle fibers using gene therapy. The most promis-
ing viral vector to introduce a micro-dystrophin cDNA in muscle 
fibers is currently the AAV vector. The results obtained with this 
vector in mice, dogs, and nonhuman primates are good despite 
the fact that antibodies against the AAV capsid were sometimes 
found in the treated animals (humans also have pre-existing anti-
bodies against AAV and adenovirus). However, a recent clinical 
trial using an AAV coding for micro-dystrophin did not demon-
strate significant transgene expression in the treated DMD patient 
muscles. Moreover, this study detected lymphocytes reacting with 
dystrophin in response to transgene expression.123
One way to eventually avoid the potential toxicity following 
the dissemination of viral vectors throughout the body158 is to 
transplant autologous cells, which have been genetically modified 
ex vivo. This ex vivo gene therapy has shown positive results in 
mice and nonhuman primates but is nevertheless limited by the 
same problems as myoblast transplantation, i.e., the difficulty of 
reaching small muscles and the high number of injection trajecto-
ries necessary to obtain a high percentage of dystrophin-positive 
fibers. Exon skipping can also be induced by viral vectors carrying 
the U7 snRNA gene modified to target a specific exon. Since no 
results are yet available in large animals with this gene, the AO 
technology currently remains the most efficient and most fre-
quently used method to induce exon skipping in DMD.
An alternative to ex vivo gene therapy is the use of naked 
plasmid delivered by hydrodynamic pressure or by electropora-
tion. These two techniques have shown good efficiency to deliver 
dystrophin cDNA or internally deleted versions of it in mouse 
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model, although these physical methods are less efficient than 
systemic injection of viral vectors. Moreover, only a few prelimi-
nary results are available in larger animal models, such as dogs 
and nonhuman primates. The main limiting factor for electropo-
ration is that at this time only a small number of muscle fibers 
can be treated with this technique since it requires penetration 
with electrodes into each muscle. The hydrodynamic method can 
be applied only to arm and leg muscles but not to muscles of the 
head and trunk.
response to dystrophin in clinical trials
During clinical trials on DMD patients, anti-dystrophin antibod-
ies were observed following nondystrophic myoblast transplan-
tation159 and dystrophin-specific T-cells were detected following 
the injection of AAV coding for micro-dystrophin. The presence 
of dystrophin-specific T-cells was also detected in one patient 
after treatment with gentamicin.123 No anti-dystrophin antibod-
ies were found in the DMD patients treated with AVI-4658 or 
with PRO051 but the presence of dystrophin-specific T-cells was 
not investigated. Apparently, there were no T-cell responses, or 
if there were, it was not effective enough to hamper dystrophin 
expression. This seems to indicate that if a therapeutic approach 
is effective to restore dystrophin in muscle fibers, some DMD 
patients may have to be under a sustained immunosuppression 
treatment.
conclusion
Even though the DMD gene was discovered 23 years ago, there are 
still no curative treatments for DMD although the use of steroids 
and assisted ventilation have greatly improved the quality of life 
and extended life span by nearly 50%.33
When a therapeutic approach is found to restore dystrophin 
in the DMD patient’s muscles, the problems of fat infiltration 
or fibrosis in the muscles will still need to be resolved, as well as 
the existing muscle weakness or bone deformation. An approach 
to improve muscle strength is to block the myostatin pathway. 
Indeed, myostatin inhibition leads to muscle hypertrophy and 
muscle strength increases in animals. The process of fat infiltra-
tion and fibrosis in DMD patient’s muscles is not well understood 
and needs to be further investigated. The best approach will thus 
be to treat DMD patients when they are still young to avoid most 
of the consequences due to the absence of dystrophin. Moreover, 
all muscles (or a large proportion of them) will need to be treated 
to obtain a curative treatment.
suPPleMentAry MAterIAl
Figure S1. AOs used in DMD.
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